![Two men, seated indoors around a table, engaged in a conversation and playing chess Two men, seated indoors around a table, engaged in a conversation and playing chess](/sites/novartis_com/files/styles/cards_1_3/public/2023-11/young-and-senior-men-playing-chess-and-laughing.jpg.webp?itok=qlEDLubb)
Discover our medicines
Our innovative medicines address society’s greatest disease burdens and restore possibility for patients.
![A female research scientist in a lab looking at a sample A female research scientist in a lab looking at a sample](/sites/novartis_com/files/styles/cards_1_3/public/2023-11/portrait-research-scientist-cambridge.jpg.webp?itok=XGxCz1ar)
Explore our science
Discover how we unravel the mysteries of biology and develop new technologies to fight disease and change lives.
![Group of warm clothed women, seated outside, smiling and laughing Group of warm clothed women, seated outside, smiling and laughing](/sites/novartis_com/files/styles/cards_1_3/public/2023-11/group-of-warm-clothed-people-smilling-and-laughing.jpg.webp?itok=wVBQo2cD)
Learn about our impact
Creating a medicine is just the beginning of the journey. Discover how we embrace societal impact as a core business objective.
![Our Pride Employee Resource Group leads in Basel with Shreeram Aradhye, President Development, Chief Medical Officer and Novartis Executive Committee Sponsor for LGBTQI+ Equity. Our Pride Employee Resource Group leads in Basel with Shreeram Aradhye, President Development, Chief Medical Officer and Novartis Executive Committee Sponsor for LGBTQI+ Equity.](/sites/novartis_com/files/styles/cta_image/public/2024-06/pride-2024-group-image.jpg.webp?itok=UmY-QAxD)
Pride 2024 | We belong here
This Pride Month, we’re shining a light on the impact of our Pride Employee Resource Groups and the power of community to drive positive change.
![3D Illustration of molecules 3D Illustration of molecules](/sites/novartis_com/files/styles/cta_image/public/2023-06/asco-home-desktop-banner.jpg.webp?itok=T-J1_hXx)
2024 ASCO Annual Meeting
Novartis attended the 2024 ASCO Annual Meeting from May 31 to June 4, 2024
Latest news
Latest analysis of Novartis NATALEE study shows Kisqali® reduces risk of cancer recurrence for early breast cancer patients with high-risk node-negative disease
Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria
The burden of IgAN
IgAN nephropathy (IgAN) is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide. Novartis is working to slow the progression of this disease and extend a dialysis-free life in patients.
![Shanelle Gabriel spending time with her father in New York Shanelle Gabriel spending time with her father in New York](/sites/novartis_com/files/styles/cta_image/public/2024-01/shanelle-gabriel-sitting-on-bench-with-her-father-new-york.jpg.webp?itok=kGsAkDwD)
Novartis in Society Integrated Report 2023
Learn about our business, strategy and performance in 2023, and how we create sustainable value for stakeholders and society.